NuVasive Stock News

Globus Medical GMED, -1.18% said Thursday it will pay 0.75 a share of its stock for each share of NuVasive NUVA, -2.41% stock in a deal that values NuVasive at about $3.1 billion or $57.72 a share. Gl

NuVasive (NUVA) believes that its 2022 guidance is appropriately conservative, considering macroeconomic pressures on net sales and operating profit.

NuVasive is a strong medical technology play driven by its revenue growth opportunities in the area of less invasive spine surgery. The company's modern less invasive spine surgery techniques can boos

The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.

The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.

Analysts have provided the following ratings for NuVasive (NASDAQ:NUVA) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 4 4 0 0 Last 3

Atlantic Equities boosted the price target on Bristol-Myers Squibb Company (NYSE: BMY) from $85 to $88. Atlantic Equities analyst Steve Chesney maintained the stock with an Overweight. Bristol-Myers

NuVasive (NASDAQ:NUVA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 3 0 0 Last 30D 1 1

NuVasive (NUVA) delivered earnings and revenue surprises of 1.89% and 0.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

NuVasive, Inc. (NASDAQ:NUVA ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Juliet Cunningham - Vice President-Investor Relations Chris Barry - Chief Executive Offi

NuVasive (NUVA) delivered earnings and revenue surprises of 1.89% and 0.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

The third-quarter results of Cigna (CI) are likely to reflect a rise in total medical customers.

The share price declined by ~46% since the beginning of the coronavirus pandemic crisis in 2020. Revenues returned to the growth path thanks to high R&D expenses and acquisitions.

Boston Scientific (BSX) delivered earnings and revenue surprises of -2.27% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO , Oct. 25, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integr